Gliomas are the most common central nervous system tumours; they are highly aggressive and have a poor prognosis. RGS16 belongs to the regulator of G-protein signalling (RGS) protein family, which plays an important role in promoting various cancers, such as breast cancer, pancreatic cancer, and colorectal cancer. Moreover, previous studies confirmed that let-7c-5p, a well-known microRNA, can act as a tumour suppressor to regulate the progression of various tumours by inhibiting the expression of its target genes. However, whether RGS16 can promote the progression of glioma and whether it is regulated by miR let-7c-5p are still unknown. Here, we confirmed that RGS16 is upregulated in glioma tissues and that high expression of RGS16 is associated with poor survival. Ectopic deletion of RGS16 significantly suppressed glioma cell proliferation and migration both in vitro and in vivo. Moreover, RGS16 was validated as a direct target gene of miR let-7c-5p. The overexpression of miR let-7c-5p obviously downregulated the expression of RGS16, and knocking down miR let-7c-5p had the opposite effect. Thus, we suggest that the suppression of RGS16 by miR let-7c-5p can promote glioma progression and may serve as a potential prognostic biomarker and therapeutic target in glioma.
Humans ; Phosphatidylinositol 3-Kinases/metabolism* ; Proto-Oncogene Proteins c-akt/metabolism* ; MicroRNAs/metabolism* ; Glioma/genetics* ; Genes, Tumor Suppressor ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Cell Line, Tumor

ObjectiveTo analyze the epidemic characteristics of foodborne disease outbreaks in Mengla County， Yunnan Province， so as to provide basis for formulating corresponding prevention and control measures. MethodsThe data of foodborne disease outbreaks in Mengla County， Yunnan Province from 2017 to 2021 in the national "foodborne disease outbreak monitoring system" were collected. The time， population， region， place， pathogenic factors and inducing links of the events were statistically analyzed. ResultsFrom 2017 to 2021， a total of 68 incidents were reported， including 526 cases and 5 deaths. The total incidence rate was 23.40% and the case fatality rate was 0.95%. The peak period was from May to July， with the largest number of reported events in July. The reporting areas were mainly Mengla Town （35.29%）， Guanlei Town （11.76%） and Mengpeng Town （10.29%）. The main place of the incident was family （76.47%）. The main pathogenic factors were plant toxins （79.41%）， mainly through the ingestion of wild mushrooms （68.52%）， improper processing of green beans （12.96%） and aconitum （9.26%）. ConclusionAccording to the epidemiological characteristics of Mengla County， we should focus on the public education of health knowledge in key areas and places， especially on the identification of wild mushrooms， to prevent accidental eating. At the same time， we should strengthen the monitoring and risk assessment of foodborne diseases， find potential risks as soon as possible， issue early warning and forecast in time， and constantly improve the clinical treatment ability of poisoned patients.

Objective:To analyze the perinatal risks for the surviving infant of dichorionic twins vanishing twin syndrome (VTS) conceived by assisted reproductive technology (ART).Methods:We used a retrospective cohort study to analyze the clinical data of 4922 frozen-thawed embryo transfer (FET)/fresh embryo transfer cycles in the Department of Reproductive Medicine of the Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2013 to December 2018. This study assessed 4922 cycles (3116 singleton live births from FET cycles and 1806 singleton live births from fresh embryo transfer cycles). The fresh embryo transfer cycles included 1000 singletons following cleavage-stage SET and 806 survivors of VTS following cleavage-stage double embryo transfer (DET). The FET cycles included 2445 singletons (613 cleavage-stage embryo transfer cycles and 1832 blastocyst transfer cycles) following single embryo transfer (SET) and 671 survivors of VTS (385 cleavage-stage embryo transfer cycles and 286 blastocyst transfer cycles) following DET. Baseline characteristics and obstetric outcomes, including gestational age, preterm birth, birth weight, low birth weight, and small-for-gestational-age were analyzed between the two groups.Results:In frozen-thawed blastocyst transfer cycles, VTS group had lower birth weight [(3 316.82±617.69) g vs. (3 405.16±550.68) g, P=0.013] and higher risk of low birth weight [a OR(95% CI)=2.70(1.46-5.00), P=0.002] compared with control group, but no differences of perinatal outcomes were found between VTS and control groups in cleavage-stage tansfer cycles. Conclusion:Surviving infant of dichorionic twins VTS may have higher perinatal risks in blastocyst-stage FET. Selective SET is recommended to obtain singleton pregnancies with a more favorable pregnancy outcome from ART.

Objective:To analyze the perinatal risks for the surviving infant of dichorionic twins vanishing twin syndrome (VTS) conceived by assisted reproductive technology (ART).Methods:We used a retrospective cohort study to analyze the clinical data of 4922 frozen-thawed embryo transfer (FET)/fresh embryo transfer cycles in the Department of Reproductive Medicine of the Affiliated Drum Tower Hospital of Nanjing University Medical School from January 2013 to December 2018. This study assessed 4922 cycles (3116 singleton live births from FET cycles and 1806 singleton live births from fresh embryo transfer cycles). The fresh embryo transfer cycles included 1000 singletons following cleavage-stage SET and 806 survivors of VTS following cleavage-stage double embryo transfer (DET). The FET cycles included 2445 singletons (613 cleavage-stage embryo transfer cycles and 1832 blastocyst transfer cycles) following single embryo transfer (SET) and 671 survivors of VTS (385 cleavage-stage embryo transfer cycles and 286 blastocyst transfer cycles) following DET. Baseline characteristics and obstetric outcomes, including gestational age, preterm birth, birth weight, low birth weight, and small-for-gestational-age were analyzed between the two groups.Results:In frozen-thawed blastocyst transfer cycles, VTS group had lower birth weight [(3 316.82±617.69) g vs. (3 405.16±550.68) g, P=0.013] and higher risk of low birth weight [a OR(95% CI)=2.70(1.46-5.00), P=0.002] compared with control group, but no differences of perinatal outcomes were found between VTS and control groups in cleavage-stage tansfer cycles. Conclusion:Surviving infant of dichorionic twins VTS may have higher perinatal risks in blastocyst-stage FET. Selective SET is recommended to obtain singleton pregnancies with a more favorable pregnancy outcome from ART.

Objective: This systematic review and meta-analysis was undertaken to evaluate the efficacy of antibacterial photodynamic therapy (aPDT) in the treatment of periodontitis in type-2 diabetes mellitus (T2DM) patients and to provide better treatment for patients with T2DM complicated with periodontitis. Methods: The PubMed, Cochrane, Embase, Web of Science, CNKI, CBM, and Wanfang databases were searched for relevant randomized controlled trials (RCTs). RevMan 5.3 was applied for the meta-analysis, and a systematic evaluation was conducted. Results: A total of 8 RCTs were included. The results showed that compared to simple subgingival scaling and root planing (SRP), aPDT assisted SRP had a better effect on improving the probing depth (PD) at 3 months after treatment, The difference was statistically significant [WMD=-0.32,95%CI（-0.45, -0.2）, P < 0.05], but 6 months after treatment, there was no significant difference in the two groups [ WMD=-0.15,95%CI（-0.40, 0.10）,P=0.23]. During the 6-month follow-up period, there were no significant differences in the clinical attachment level (CAL), bleeding on probing (BOP) or hemoglobin A1c (HbA1c) between the two groups (P> 0.05). Conclusion aPDT-assisted periodontal nonsurgical treatment in T2DM patients can improve PD in the short term but has no significant effect on the improvement of CAL, BOP and HbA1c.

Objective:To study the predictive value of the amplitude-integrated electroencephalography (aEEG) within 6 hours and 3 days after birth and magnetic resonance imaging(MRI) on the adverse neurobehavioral development of asphyxiated preterm infants at the correction age of 6 months.Methods:From December 2017 to June 2019, 50 asphyxiated preterm infants who were delivered at the obstetrical department transferred to the division of neonatology in the Third Affiliated Hospital of Anhui Medical University were monitored by aEEG within 6 hours after birth, then once a day for at least 4 h. MRI was administered at 40 weeks of corrected age, neuromotor developmental function of the infants was assessed by the Geisel developmental diagnostic scale at 6 months of corrected age, then the infants were divided into good prognosis group and poor prognosis group according to the assessment results. SPSS 19.0 software was used for statistical analysis.The software of SPSS 19.0 was used to analyze the data.Independent sample t-test and χ 2 test were used to analyze the difference between the two groups.The relationship between aEEG grading and MRI, and their predictive value for adverse neurobehavioral development were analyzed at 6 months of corrected age. Results:The degree of white matter damage( H=24.896) and intracranical hemorrhage( H=29.245) of premature infants with different aEEG clinical grades were different (both P<0.01) on MRI. The sensitivity of aEEG within 6 hours and 3 days after birth on predicting poor prognosis was 96.2% and 97.8%, the specificity was 56.2% and 62.5%, the negative predictive value was 98.2% and 99.0%, the positive predictive value was 37.8% and 52.3%, the correct index was 52.4% and 60.3%, respectively. The aEEG was combined with MRI, the sensitivity (90.0%, 97.0%), specificity (89.0%, 99.0%), negative predictive value (99.2%, 99.5%), positive predictive value (80.6%, 88.5%), and correct index (79%, 96%) were all improved. Conclusion:The combination of aEEG grading and MRI can improve the prognostic value on neurodevelopmental prognosis, and provide a better evaluation basis for clinical follow-up and intervention of asphyxiated premature infants with brain injury.

Objective:To explore the effect of dose adjustment based on doxofylline blood concentration monitoring on safety of combination of doxofylline and terbutaline for respiratory diseases.Methods:The subjects were selected from patients who received doxofylline injection, terbutaline sulphate solution for nebulizationor, and the combination of the two drugs and hospitalized in Department of Respiratory Medicine of Zhengzhou Second People′s Hospital from January 1, 2014 to December 31, 2018. Patients who met the inclusion criteria were divided into 3 groups: doxofylline group, terbutaline group, and combination of doxofylline and terbutaline group (combination group). All patients in the 3 groups were given conventional treatments and symptomatic treatments. Doxofylline 300 mg once daily was given by an IV infusion and terbutaline 2 ml (5 mg) thrice daily was given by atomized inhalation for 7-14 days. Adverse reactions in the 3 groups were compared. The dosage of doxofylline in patients with adverse reactions of grade 1 was adjusted to 250 mg once daily, 200 mg once daily for patients with adverse reactions of grade 2, and doxofylline was stopped in patients with adverse reactions of more than grade 3. The blood concentration of doxofylline, the proportion of the patients whose adverse reactions were alleviated or disappeared, the length of hospital stay, and the efficiency of treatment before and after dose adjustment of doxofylline in patients in the doxofylline group and the combination group were compared.Results:A total of 6 582 patients were entered in the study. Of them, 1 438 patients were in the doxofylline group, including 793 males and 645 females with age of (61±11) years; 2 217 patients were in the terbutaline group, including 1 281 males and 936 females with age of (60±15) years; 2 927 patients were in the combination group, including 1 644 males and 1 283 females with age of (63±12) years. The differences in gender, age distribution, basic disease, combined disease, and combination medication among the 3 groups were not statistically significant ( P>0.05). The overall incidences of adverse reactions in the 3 groups were 13.1% (189/1 438), 8.9% (197/2 217), and 21.2% (620/2 927), respectively, which was higher in the combination group than that in the doxofylline group ( χ 2=41.271, P<0.001) and the terbutaline group ( χ 2=142.766, P<0.001) and higher in the doxofylline group than that in the terbutaline group ( χ 2=16.738, P<0.001). The incidences of tremor and headache in the combination group were higher than those in the other 2 groups( P<0.001), the incidence of hyperglycemia was higher than that in the doxofylline group( P=0.003), the incidence of insomnia was higher than that in the terbutaline group( P<0.001), the incidence of tachycardia was higher than that in the terbutaline group( P<0.001), the incidence of nausea was lower than that in the doxofylline group( P<0.001) and higher than that in the terbutaline group( P<0.001), the incidence of mood disorders was higher than that in terbutaline group ( P=0.017). No adverse reactions of more than grade 3 occurred in the 3 groups, the difference in proportions of patients with adverse reactions of grade 1 and grade 2 was not statistically significant( χ 2=1.097, P=0.578). The difference in blood concentration of doxofylline in patients with adverse reactions between the combination group and the doxofylline group was not statistically significant before dose adjustment ( P>0.05), but all decreased after dose adjustment (all P<0.001) and the blood concentration of doxofylline in the combination group was lower than that in the doxofyllin group [(8.38±2.19) μg/ml) vs. (10.64±2.55) μg/ml, P<0.001]; the proportion of patients whose adverse reactions were alleviated or disappeared in the combination group was higher than that in the doxofylline group [40.81% (253/620) vs. 30.16% (57/189), P=0.008], the hospitalization time was shorter than that in the doxofylline group [(10±2) d vs. (15±3) d, P<0.001], the treatment efficiency was higher than that in the doxofylline group [531 (85.65%) vs. 136 (71.96%), P<0.001]. Conclusion:When doxofylline injection is combined with terbutaline solution for nebulizationor, the blood concentration of doxofylline can be controlled at (8.38±2.19) μg/ml by monitoring the blood concentration of doxofylline, which can not only improve the treatment efficacy, but also improve the medication safety.

A 24-year-old female patient took about 150 carbamazepine tablets (15 g). About 17 hours later, she was found unconscious and frequent convulsions by her family and was immediately sent to the hospital. Laboratory tests showed that the serum concentration of carbamazepine was 58.7 mg/L, creatine kinase was 411 U/L, C-reactive protein was 23.7 mg/L, and blood oxygen saturation was 0.78. Toxic encephalopathy and status epilepticus induced by carbamazepine were diagnosed. Oxygen inhalation, ECG monitoring, intravascular fluid supplement, diuresis, bedside blood filtration, and symptomatic and supportive treatments were given immediately. On the 2nd day, the number of epileptic seizures decreased and the serum concentration of carbamazepine decreased to 32.9 mg/L. On the 3rd day, the patient′s consciousness recovered and seizures occurred occasionally; on the 4th day, the serum concentration of carbamazepine decreased to 12.3 mg/L, and her convulsion disappeared. After 3 days of continued treatments, the patient recovered and discharged.

Objective:To explore the effect of dose adjustment based on doxofylline blood concentration monitoring on safety of combination of doxofylline and terbutaline for respiratory diseases.Methods:The subjects were selected from patients who received doxofylline injection, terbutaline sulphate solution for nebulizationor, and the combination of the two drugs and hospitalized in Department of Respiratory Medicine of Zhengzhou Second People′s Hospital from January 1, 2014 to December 31, 2018. Patients who met the inclusion criteria were divided into 3 groups: doxofylline group, terbutaline group, and combination of doxofylline and terbutaline group (combination group). All patients in the 3 groups were given conventional treatments and symptomatic treatments. Doxofylline 300 mg once daily was given by an IV infusion and terbutaline 2 ml (5 mg) thrice daily was given by atomized inhalation for 7-14 days. Adverse reactions in the 3 groups were compared. The dosage of doxofylline in patients with adverse reactions of grade 1 was adjusted to 250 mg once daily, 200 mg once daily for patients with adverse reactions of grade 2, and doxofylline was stopped in patients with adverse reactions of more than grade 3. The blood concentration of doxofylline, the proportion of the patients whose adverse reactions were alleviated or disappeared, the length of hospital stay, and the efficiency of treatment before and after dose adjustment of doxofylline in patients in the doxofylline group and the combination group were compared.Results:A total of 6 582 patients were entered in the study. Of them, 1 438 patients were in the doxofylline group, including 793 males and 645 females with age of (61±11) years; 2 217 patients were in the terbutaline group, including 1 281 males and 936 females with age of (60±15) years; 2 927 patients were in the combination group, including 1 644 males and 1 283 females with age of (63±12) years. The differences in gender, age distribution, basic disease, combined disease, and combination medication among the 3 groups were not statistically significant ( P>0.05). The overall incidences of adverse reactions in the 3 groups were 13.1% (189/1 438), 8.9% (197/2 217), and 21.2% (620/2 927), respectively, which was higher in the combination group than that in the doxofylline group ( χ 2=41.271, P<0.001) and the terbutaline group ( χ 2=142.766, P<0.001) and higher in the doxofylline group than that in the terbutaline group ( χ 2=16.738, P<0.001). The incidences of tremor and headache in the combination group were higher than those in the other 2 groups( P<0.001), the incidence of hyperglycemia was higher than that in the doxofylline group( P=0.003), the incidence of insomnia was higher than that in the terbutaline group( P<0.001), the incidence of tachycardia was higher than that in the terbutaline group( P<0.001), the incidence of nausea was lower than that in the doxofylline group( P<0.001) and higher than that in the terbutaline group( P<0.001), the incidence of mood disorders was higher than that in terbutaline group ( P=0.017). No adverse reactions of more than grade 3 occurred in the 3 groups, the difference in proportions of patients with adverse reactions of grade 1 and grade 2 was not statistically significant( χ 2=1.097, P=0.578). The difference in blood concentration of doxofylline in patients with adverse reactions between the combination group and the doxofylline group was not statistically significant before dose adjustment ( P>0.05), but all decreased after dose adjustment (all P<0.001) and the blood concentration of doxofylline in the combination group was lower than that in the doxofyllin group [(8.38±2.19) μg/ml) vs. (10.64±2.55) μg/ml, P<0.001]; the proportion of patients whose adverse reactions were alleviated or disappeared in the combination group was higher than that in the doxofylline group [40.81% (253/620) vs. 30.16% (57/189), P=0.008], the hospitalization time was shorter than that in the doxofylline group [(10±2) d vs. (15±3) d, P<0.001], the treatment efficiency was higher than that in the doxofylline group [531 (85.65%) vs. 136 (71.96%), P<0.001]. Conclusion:When doxofylline injection is combined with terbutaline solution for nebulizationor, the blood concentration of doxofylline can be controlled at (8.38±2.19) μg/ml by monitoring the blood concentration of doxofylline, which can not only improve the treatment efficacy, but also improve the medication safety.

A 24-year-old female patient took about 150 carbamazepine tablets (15 g). About 17 hours later, she was found unconscious and frequent convulsions by her family and was immediately sent to the hospital. Laboratory tests showed that the serum concentration of carbamazepine was 58.7 mg/L, creatine kinase was 411 U/L, C-reactive protein was 23.7 mg/L, and blood oxygen saturation was 0.78. Toxic encephalopathy and status epilepticus induced by carbamazepine were diagnosed. Oxygen inhalation, ECG monitoring, intravascular fluid supplement, diuresis, bedside blood filtration, and symptomatic and supportive treatments were given immediately. On the 2nd day, the number of epileptic seizures decreased and the serum concentration of carbamazepine decreased to 32.9 mg/L. On the 3rd day, the patient′s consciousness recovered and seizures occurred occasionally; on the 4th day, the serum concentration of carbamazepine decreased to 12.3 mg/L, and her convulsion disappeared. After 3 days of continued treatments, the patient recovered and discharged.